Comerica Bank’s Design Therapeutics DSGN Stock Holding History

Comerica Bank’s Portfolio DSGN Stock Details DSGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-549	Closed	-$1.3K	–	3753
2023 Q3	$1.3K	Buy	+549	New	+$2.56K	﹤0.01%	3637

Other funds holding DSGN

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Comerica Bank's DSGN Position: Q4 2023 in Review

Comerica Bank sold out of Design Therapeutics (DSGN) in Q4 2023, closing a stake of 549 shares — an estimated $1.3K sold.

Comerica Bank first reported a position in DSGN in Q3 2023 and held it in 1 quarter. The position peaked at $1.3K in Q3 2023. 88 funds tracked by Wall St. Rank hold DSGN as of Q4 2023.

Comerica Bank reported no remaining Design Therapeutics position as of Q4 2023 after selling out during the quarter.
Comerica Bank sold 549 Design Therapeutics shares in Q4 2023, an estimated $1.3K.
Comerica Bank first reported a position in Design Therapeutics in Q3 2023 and held it in 1 quarter.
Comerica Bank's Design Therapeutics position peaked at $1.3K in Q3 2023.
88 funds tracked by Wall St. Rank held Design Therapeutics as of Q4 2023.

Based on Comerica Bank's 13F filing for Q4 2023, filed 14 Feb 2024.